Global Syphilis Testing Market 2023-2030

Global Syphilis Testing Market 2023-2030

Global Syphilis Testing Market Size, Share & Trends Analysis Report by Type (Primary and Secondary Syphilis, Latent and Tertiary Syphilis), by Location of Testing (Laboratory Testing, Point-of-Care (POC) Testing), and by Technology (Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Nucleic Acid Amplification Test (NAAT), and Others), by End User (Hospitals, Diagnostic Labs, Home Care), Forecast Period (2023-2030)

The global syphilis testing market is anticipated to grow at a CAGR of 6.2% during the forecast period (2023–2030). Treponema palladium is the bacterium that causes the sexually transmitted disease syphilis. During the first two phases, it is most contagious. The initial stage of syphilis is the concealed, or latent, stage, during which the patient is not harmed. Although there are no symptoms, the disease is still vital. The second stage of the disease, referred to as tertiary syphilis, is the most harmful to health. Some main driving factor that accelerating the market include the rising prevalence of sexually transmitted infections (STDs), the rise in miscarriages, and the rising demand for efficient disease diagnostic and testing solutions in the healthcare industry. As a result, market participants are concentrating on technology developments when creating syphilis testing products and accompanying service portfolios, which will further support market expansion. For Instance, In February 2023, to combat the rise of STIs on college campuses, Caraway and Ash Wellness started a partnership. tests for STIs and sexually transmitted infections (STIs), such as chlamydia, gonorrhoea, syphilis, HIV, hepatitis C, trichomoniasis, candidiasis, and bacterial vaginosis, are included in the kits.

Segmental Outlook

The global syphilis testing market is segmented on the type, location of testing, technology, and end-users. Based on the type, the market is sub-segmented into primary & secondary syphilis and latent & tertiary syphilis. Based on the location of testing, the market is sub-segmented laboratory testing and point-of-care (POC) testing. Further, on the basis of technology, the market is sub-segmented into CLIA, ELISA, NAATs, and others. By end-user, the market is sub-segmented into hospitals, diagnostic labs, and home care.

The Laboratory Testing Sub-Segment is Anticipated to Hold a Considerable Share of the Global Syphilis Testing Market

Among the location of testing, the laboratory testing sub-segment is expected to hold a considerable share of the global syphilis testing market. The segmental growth is attributed to the growing influence of several serological tests, rapid plasma regain (RPR) test, and Treponema pallidum particle agglutination (TPPA) test, and advancements in laboratory testing technologies and the availability of automated systems have improved the efficiency and turnaround time of syphilis testing. Healthcare campaigns, educational programs, and initiatives by governments and healthcare organizations have emphasized the significance of syphilis testing. According to the National Institute of Health (NIH), The nontreponemal test will typically be positive in situations of active syphilis, and a titter will be carried out. When a follow-up serologic test reveals a positive titter with a VDRL or RPR, it indicates that syphilis is active, and it is used to track treatment effectiveness. For instance, in February 2023, the maternal and child health company Maternova established a distribution partnership with MedMira, a creator and manufacturer of quick diagnostic tests for STIs diseases like HIV, hepatitis, syphilis, and others with headquarters in Nova Scotia, Canada.

Regional Outlook

The global syphilis testing market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market across the globe, owing to the continuously growing healthcare industry coupled with rise in establishment of efficient healthcare infrastructure.

The North America Region is Expected to Grow at a Significant CAGR in the Global Syphilis Testing Market

Among all regions, North America is anticipated to grow at a considerable CAGR over the forecast period. North America, and particularly the US, will continue to play a crucial role that cannot be disregarded. The regional growth is attributed to the widespread use of modern technologies and the presence of major competitors in the region, which offers several opportunities of expansion for market players. For instance, in March 2023, a dual HIV-syphilis fast test was recently approved by Health Canada after a two-year clinical trial revealed that it was 100% accurate at detecting HIV infections and 98% accurate in detecting active syphilis. Rapid testing for sexually transmitted illnesses has excitingly advanced with the DPP HIV-Syphilis System. The DPP HIV-Syphilis System is currently available to more than 200,000 CLIA-waived point-of-care testing facilities in the US. Another factor bolstering the market growth is owing to the rising MSM (men having sex with men) cases along with the implementation of screening tests as a requirement for pregnant women.

Market Players Outlook

The major companies serving the syphilis testing market include Abbott laboratories, Bio-Rad laboratories Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Hologoic Inc. and others. By using a variety of techniques, including as mergers and acquisitions, partnerships, collaborations, funding, and the launch of new products, companies in the industry are significantly boosting market growth. For instance, in March 2023 Health Canada grants authorization to bioLytical laboratories Inc. for its INSTI® Multiplex HIV-1/2 syphilis antibody test. The test lessens test anxiety for patients by enabling medical practitioners to test more people in less time by providing results for two infections with just one sample.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global syphilis testing market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.